Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Prothena ( (PRTA) ).
On August 27, 2025, Prothena announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012, aimed at treating early symptomatic Alzheimer’s disease. The study demonstrated that PRX012, a once-monthly, subcutaneous anti-amyloid beta antibody, showed promising results in reducing amyloid plaque but had higher ARIA-E rates compared to FDA-approved antibodies. Prothena plans to seek partnerships to further develop PRX012 and its preclinical PRX012-TfR antibody, which may offer a reduced risk of ARIA and quicker amyloid plaque reduction.
The most recent analyst rating on (PRTA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
Spark’s Take on PRTA Stock
According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.
Prothena’s overall stock score is primarily impacted by its financial instability, with declining revenue and negative profit margins. While technical indicators show some bullish momentum, the valuation remains unattractive due to negative earnings. Corporate events provide a mixed outlook, with promising drug advancements offset by operational challenges.
To see Spark’s full report on PRTA stock, click here.
More about Prothena
Prothena Corporation plc is a biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer’s disease. The company is engaged in the research and development of investigational drugs, with a particular focus on anti-amyloid beta antibodies.
Average Trading Volume: 1,436,408
Technical Sentiment Signal: Sell
Current Market Cap: $449.5M
Find detailed analytics on PRTA stock on TipRanks’ Stock Analysis page.